The Great White Green Rush: Canadian Cannabis Ventures in America
fortune420.com | Jan 25, 2017
The new year has not only brought the US a new president, but we’re seeing the next revolution in the Cannabis Market.
Marijuana reforms flooded the state legislature and we have seen more than a dozen states loosen laws reflecting the newfound willingness to embrace the trend toward legalization. This is not just in the US, but also our friendly neighbors up North.
Canada Takes Next Step Toward National Marijuana Legalization Analysts predict Canada could have $4.5 billion industry by 2021; marijuana task force wraps up extensive report that is expected to include recommendations on everything from age limits to medical marijuana, safety and home grows.
A legal market for recreational marijuana could give Canada’s economy a boost of up to $22.6 billion annually, says a new study from business services firm Deloitte.
The study estimates that marijuana sales, even initially, would be at least as large as hard liquor sales in Canada, at around $5 billion annually, but could be as large as $8.7 billion, making them as large as wine sales. Bloomberg reports that Canada will become the First G7 Nation to Fully Legalize Weed this Year.
Check out the video below:
Marapharm Ventures Inc. (OTCQB: MRPHF) is poised to capitalize on it and is set to exploit both the American and Canadian Cannabis Markets
Marapharm Ventures Inc. (OTCQB: MRPHF) is a truly remarkable opportunity. The company has applied to Health Canada to become a licensed producer under the Marijuana for Medical Purposes Regulations (MMPR) issued pursuant to the Controlled Drugs and Substances Act (Canada). The application is currently in the in-depth screening process.
In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR. Marapharm’s initial facility, a proposed 22,000 square foot state-of-the-art designed-to-suit cultivation facility, will be constructed on an 11 acre leased site in Kelowna, British Columbia.
MRPHF ‘s growth strategy will be to build facilities or acquire licenses in the United States, determined by identifying opportunities and researching the direction and location of sales. The company has currently focused its attention on opportunities in Nevada and Washington.
MRPHF Is More Than Just A Cannabis Opportunity; They own Real Estate, Health and Wellness Supplements, and Retail Dispensaries
MRPHF has also purchased and is developing an all-natural hemp oil product line called, Maragold, which will be ready for market within a few months.
Such impressive growth fosters the need for a strategically aligned partner. Look no further than the past few weeks. Wall Street may have missed this but not us.
GROWTH: Marapharm Ventures, Inc. (MRPHF) Increases Investment Position in Veritas Pharma
MRPHF has invested heavily into Veritas Pharma Inc. Veritas Pharma Inc, a company which aims to develop the most effective proprietary cannabis strains for specific disease conditions, and to provide doctors and patients with conclusive scientific evidence to recommend and use medical marijuana with confidence, advancing the science behind medical marijuana.
Marapharm Ventures Inc. (MRPHF) (MDM.CN) (“Marapharm”) announces that is has entered into a subscription agreement to acquire 5 million 18 month $0.30 share purchase warrants of Veritas Pharma Inc. for consideration of $250,000.
“We like the Veritas Pharma business model and we know that we can play a big role in their growth. Marapharm has acquired shares and rights to acquire up to 15 million shares of Veritas, after taking into account 10 million share purchase warrants that we have. As a result of the investment, Marapharm will have the right to appoint members to the Veritas board of directors. There’s great synergy with Veritas and Marapharm and the additional investment in the share purchase warrants will provide additional capital to Veritas as they execute on their business plan.” Linda Sampson, Marapharm CEO.
On January 9, 2017 Marapharm announced that it had subscribed for 5 million units in a private placement offering of Veritas Pharma Inc., each unit consisting of 1 share and 1 share purchase warrant.
The share purchase warrants acquired by Marapharm were acquired for investment purposes and Marapharm may, in its discretion acquire further securities of Veritas.
As of New Years 2017, What happens in Vegas doesn’t always stay in Vegas. Marapharm has a growing footprint in the US Market is expanding the business model to include “vertical plus” farming in its Nevada and Washington marijuana facilities.
Marapharm Ventures Inc. (“Marapharm” or the ” Company”) MARAPHARM VENTURES INC. (OTCQB:MRPHF), (CNSX:MDM.CN), (FSE:2M0) (http://www.marapharm.com/) announces several key developments in its wholly owned US subsidiary in Las Vegas, Nevada.
Las Vegas (Nevada) Highlights
- 3 Medical Marijuana Licenses.
- Total square footage of all licenses ~approx. 300,000 sq’ including a 16,000sq’ processing license.
- Special Use Permits have been granted for all three licenses on 5.9 acres owned by Marapharm Las Vegas LLC.
- Site work has begun, buildings are ordered, erection crew is hired
- Nevada Marijuana Legalization Initiative (also known as “Question 2”) on ballot November 8, 2016, for the legalization of recreational marijuana.
- All production at this facility is under contract to a group of dispensaries in Las Vegas.
Marapharm is also expanding into California. On November 16, the company entered into an an agreement to purchase an industrial facility in southern California and three medical marijuana licenses for manufacturing, cultivation, and retail uses.
The land size is 40,510 square feet and the existing building size is 6,875 square feet, with a 19-foot-ceiling clearance, for a purchase price of $3.2 million based on $450 per square foot for the building and $65 per square foot for the land. The yard area is paved and suitable for greenhouse growing.
Marapharm also has automated cannabis machines, which will be located within retail outlets or dispensaries in Washington and Nevada. ACMs will stock and only sell Marapharm products in states where Marapharm owns the cultivation facilities and is permitted to act as a retail dispenser.
In other areas, the machines will be leased to growers or will occupy floor space in retail outlets and dispensaries under revenue participation agreements
Beyond the Numbers: The Stats tell the Tale
- Statistics – Medical Marijuana Canada: Health Canada states that there are 40,000 registered medical marijuana patients. In a separate Government of Canada survey on drug and alcohol use, of all those questioned on the use of marijuana, 420,000 admitted that they use marijuana for a medical reason.At 1 ounce per month average cost $200 per ounce, this amounts to $84 million per year!
- Statistics – Recreational Marijuana Canada: 12.2% of Canadians use marijuana. The Canadian population is 35,154,300. There are 4,288,824 marijuana users in Canada.
- Statistics – Medical Marijuana United States: Estimated 2,434,192 patients use medical marijuana in the U.S. Calculated at a possible $200 per month patient use: $ 5.8 Billion US
- Statistics – Recreational Marijuana United States: 19.8 million users in the U.S. in the past month (drugabuse.gov). An article in the Washington Post quotes a report by Greenwave Advisors estimating, if legalized, the U.S. marijuana industry could be worth $35 Billion by 2020. To put that into perspective: The NFL is worth $10 Billion. The whole U.S. confectionary market is worth $34 Billion.
- Statistics – Recreational Marijuana Worldwide: There are an estimated 180.6 million marijuana users worldwide. The worldwide black market is estimated at $141.80 Billion.
- Statistics – Opinions: In Canada 66% of those polled feel marijuana should be legalized and taxed
In the U.S. 88% of those polled feel Medical Marijuana should be legal, 58% support legalization and taxation.
Given the strong numbers, it’s hardly surprising that many believe cannabis is the one of the hottest sectors for investors in 2017 and beyond.
Why Lawmakers Want to Legalize Marijuana’s Cousin – Marijuana legalization is still a contentious issue in Congress that few politicians have been willing to get behind. But when it comes to hemp — a close relative in the cannabis family — a bipartisan effort to deregulate the plant is moving forward.
DID YOU KNOW? Hemp has been used in healing for centuries but faced an almost world-wide ban for a large part of the twentieth century and into the early part of the 21st century. In recent years the ban is gradually being lifted and this wonder-working, broad spectrum plant is now being made available for its many therapeutic uses.
A subsidiary, Maragold health and wellness products, is a line of all natural products blended with hemp and made up of raw essential oils and natural ingredients. Why Investors Should Move On Undervalued Opportunities Now It’s safe to say that government intervention in the marijuana space is positive all around for investors.
OUTLOOK | OTCQB: MRPHF
(OTCQB: MRPHF) believes that it is well positioned in Canada and the USA to develop a future in marijuana related industries. Management’s business model is to work toward acquiring and purchasing licenses and facilities in strategic locations. Management also remains committed to providing other synergies and products for people to increase their overall quality of life.
(OTCQB: MRPHF) is optimistic about its chances to capitalize on opportunities in and profiting from the dynamic nature of the relatively new medical and recreational marijuana industry both in Canada and the United States.
Once Wall Street discovers Marapharm Ventures Inc. (OTCQB: MRPHF), the demand should be off-the-charts. Currently trading with a market cap of just over $60M, MRPHF has a ton going for it with a substantial jump on its competitors. With so many potential revenue streams, investors should, at the very least start their research on this company before the Great White Green Rush really gets Growing.
ABOUT MARAPHARM VENTURES INC. | OTCQB: MRPHF
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.
Marapharm has 300,000 square feet of medical marijuana licenses for it’s land and facilities in WA and NV and about two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (Production and Sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.
http://www.marapharm.com Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com), the OTC website (http://www.otcmarkets.com) and Sedar website (http://www.sedar.com) under the profile for Marapharm Ventures Inc.
FOR FURTHER INFORMATION: http://www.marapharm.com or Linda Sampson, CEO, +1-778-583-4476 firstname.lastname@example.org
STOCK EXCHANGES: Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
FORWARD – LOOKING STATEMENTS: Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.